Intellia Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Intellia Therapeutics, Inc. on November 8, 2025, with the latest event reported on November 10, 2025. The filing discloses positive clinical data updates for two investigational in vivo CRISPR-based gene editing therapies: lonvoguran ziclumeran (lonvo-z) for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM).
Key Financial Metrics
This filing is a regulatory disclosure regarding clinical trial results and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Updates
- Lonvoguran Ziclumeran (lonvo-z) for HAE:
- Data presented from a pooled analysis of 32 patients receiving a 50 mg dose in a Phase 1/2 trial (data cutoff: August 29, 2025).
- Mean reduction in plasma kallikrein was 89% at month 24.
- 31 of 32 patients (97%) were attack-free and long-term prophylaxis-free as of the data cutoff; 24 patients (75%) remained so for at least seven months.
- Safety profile was well-tolerated with no long-term risks identified over up to three years of follow-up. One serious adverse event (pulmonary embolism) occurred in a patient with multiple risk factors but resolved without sequelae.
- The global Phase 3 HAELO trial completed enrollment in September 2025.
- Nexiguran Ziclumeran (nex-z) for ATTR-CM:
- Data presented from a Phase 1 trial of 36 patients (data cutoff: August 23, 2025), including 9 patients with 36 months of follow-up.
- Mean serum TTR reduction was 87% at 36 months.
- At 24 months, 70% of patients showed stability or improvement in NT-proBNP, and 85% in hs-Troponin T. 81% of patients were stable or improved in NYHA classification.
- A post-hoc mortality analysis showed an all-cause mortality rate of 3.9 per 100 patient-years for the trial cohort versus 12.7 for a matched historical cohort (HR 0.27, p=0.009).
- Regulatory Status: On October 29, 2025, the FDA placed a clinical hold on the IND applications for the Phase 3 MAGNITUDE and MAGNITUDE-2 trials.
Guidance, Outlook, and Risks
Management expects to report topline data from the Phase 3 HAELO trial by mid-2026. The company is working to address the FDA clinical hold on the MAGNITUDE and MAGNITUDE-2 trials to resume development. Forward-looking statements are subject to risks including regulatory approval uncertainties, the ability to successfully complete clinical trials, intellectual property challenges, and reliance on collaborations (specifically with Regeneron Pharmaceuticals, Inc.).
Investor Verification Checklist
- Verify the status and timeline for resolving the FDA clinical hold on the MAGNITUDE and MAGNITUDE-2 trials.
- Monitor the expected mid-2026 topline data readout for the Phase 3 HAELO trial.
- Review the safety data regarding liver enzyme elevations and infusion-related reactions in the context of the Phase 3 trials.
- Assess the impact of the clinical hold on the company's cash burn rate and liquidity, as this filing does not provide updated financial metrics.
- Confirm the details of the collaboration with Regeneron Pharmaceuticals, Inc. regarding the development and commercialization of these assets.